LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1

Shuang Lin1, Rui Zhang2, Lei Xu3, Rui Ma4, Liming Xu5, Linghua Zhu6, Jian Hu1 and Xiaoxia An7

Abstract
Long noncoding RNAs (lncRNAs) participate in organ fibrosis and various pulmonary diseases, but its role in idiopathic pulmonary fibrosis (IPF) is not fully understood. In this study, we found lncRNA Hoxaas3 (Hoxaas3) was up-regulated in the mice model of BLM-induced PF and TGF-β1-induced fibrogenesis in lung fibroblasts (LF). Overexpression of Hoxaas3 promoted fibrogenesis, whereas Hoxaas3 inhibition attenuated lung fibrosis both in vitro and in vivo, through regulation of miR-450b-5p. Furthermore, miR-450b-5p inhibition stimulated fibrogenesis by regulating runt-related transcription factor 1 (Runx1), whereas up-regulation of miR-450b-5p alleviated fibrogenesis in LF. Mechanistically, our study showed that Hoxaas3 regulated lung fibroblast activation and fibrogenesis by acting as a competing endogenous RNA for miR-450b-5p: Hoxaas3 decreased the expression of miR-450b-5p to stimulate level and activity of Runx1 and induced fibrotic LF, whereas Runx1 inhibition alleviated the pro-fibrotic effect of Hoxaas3. In addition, Hoxaas3 was regulated by TGF-β1/Smad4 pathway as its transcriptional target. In conclusion, our study showed the role and mechanism of the TGF-β1/Smad4-Hoxaas3–miR-450b-5p–Runx1 axis for a better understanding of PF, demonstrated Hoxaas3 maybe a new diagnostic biomarker or potential therapeutic target for IPF.

Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial pulmonary disease of unknown reasons, often characterized primarily by excessive deposition of extracellular matrix (ECM) proteins by activated lung fibroblasts (LF) and myofibroblasts, leading to decreased exchange and impaired pulmonary function1,2. It is one of the most common idiopathic interstitial pneumonia and the most commonly interstitial pulmonary disease, with an estimated incidence of 50/100,0003,4. The majority of IPF occurs primarily in older adults, with median survival after diagnosis limited to 3–5 years6–8. There is no widely accepted treatment for IPF, although the new anti-fibrotic drugs, pirfenidone, and nintedanib, can alleviate IPF progress9. Therefore, it is essential to explore the molecular mechanisms of IPF and to discover more effective therapeutic strategies and drugs for the treatment of IPF.

Long noncoding RNAs (lncRNAs) are transcripts of more than 200 nucleotides. They have a variety of biological regulatory functions, including proliferation, differentiation, apoptosis, immune response, etc10–14, and have recently attracted widespread attention. Although many lncRNAs have crucial functions in various diseases, only a few lncRNAs have been reported to participate in pulmonary fibrosis (PF). The function and mechanisms of lncRNAs in IPF regulation remain largely unknown, and further investigation into the molecular mechanism of lncRNAs for IPF may promote the development of improved therapies.
Our study aimed to explore the role and potential mechanisms of a lncRNA, Mus musculus Hoxa cluster antisense RNA 3 (lncRNA Hoxaas3, Hoxaas3) in IPF. This research is a follow-up to a previous study performed in our laboratory. Previously, we investigated its homologous gene, HOXA-AS3, which is upregulated by cisplatin therapy, and we found that HOXA-AS3 inhibition enhanced the efficacy of cisplatin. HOXA-AS3 regulated cisplatin resistance by interacting with HOXA3, including the mRNA and protein forms, then reducing its expression. Moreover, HOXA3 inhibition raised cisplatin resistance and promoted changes in epithelial–mesenchymal transition (EMT)\textsuperscript{15}. In the current study, we found that Hoxaas3 regulated fibrogenesis by acting as a ceRNA for miR-450b-5p to regulate Runx1 in lung fibroblasts, further verifying that Hoxaas3 was a transcriptional target of the TGF-β1/Smad4 pathway. In addition, our study, for the first time, to our knowledge, demonstrated that silencing Hoxaas3 alleviated PF in vitro and in vivo. Collectively, this study elucidated the mechanism of Hoxaas3 and provided a new diagnostic biomarker or potential therapeutic target for IPF.

Results

Up-regulation of Hoxaas3 during PF in mice

Increasing literature has indicated that lncRNAs played an essential role in the process of PF. A BLM-treated PF model was established in mice to investigate the role of lncRNAs in IPF. This model was confirmed by H&E staining and Masson trichrome assay to detect collagen deposition (Fig. S1A) and increase of fibrosis area (Fig. S1B). Meanwhile, qPCR analysis displayed that the mRNA expression of collagen-1a1, collagen-3a1, and fibronectin were upregulated in the lung tissues from the BLM-induced model compared with tissues in the saline group (Fig. S1C–E). Furthermore, the fibrosis-related proteins (FRP) of fibronectin and a-SMA were also raised by western blot (Fig. S1F). These results indicated that the BLM-induced PF model in mice was successfully established. In addition, H&E staining and Masson trichrome assay for sections of the heart (Fig. S2A), liver (Fig. S2B), and kidney (Fig. S2C) showed no obvious fibrosis in the model of BLM-treated PF in mice.

A previous study showed that lncRNAs expressed differently in lung tissues of PF model in mice and normal control mice\textsuperscript{16}. Among these lncRNAs, we focused on Hoxaas3 for further studies. To further validate the results of microarray analysis, we used qPCR to study the expression of Hoxaas3 in BLM-induced animal models. Increased expression of Hoxaas3 was observed at 21 and 28 days compared with that in the saline group (Fig. 1a). HYP is an indicator of PF, and its expression was also upregulated at 14 and 28 days (Fig. 1b). The correlation between Hoxaas3 and HYP was determined by the Pearson correlation coefficient. Statistical analysis showed that Hoxaas3 was positively correlated with HYP, indicating that Hoxaas3 was positively correlated with the level of PF (Fig. 1c). Furthermore, the level of Hoxaas3 was higher in pulmonary fibrotic tissues of 18 IPF patients than 18 normal lung tissues (Fig. 1d). These results indicated that Hoxaas3 level is up-regulated in the mice model of BLM-induced PF and IPF patients. Hoxaas3 may play an important role in PF.

Silencing Hoxaas3 attenuated BLM-induced PF in mice

To investigate the therapeutic role of Hoxaas3 in PF, sh-Hoxaas3, or sh-Scram was intratracheally injected into mice on 3 days after BLM treatment. The efficiency of the sh-Hoxaas3 knockdown was evaluated by qPCR in fibroblasts (Fig. 2a), and Hoxaas3 knockdown inhibited the up-regulation of Hoxaas3 in BLM-induced mice (Fig. 2b). Moreover, Hoxaas3 inhibition reduced collagen deposition (Fig. 2c), fibrotic area (Fig. 2d), and HYP (Fig. 2e) in the BLM-induced mice. Meanwhile, Hoxaas3 knockdown alleviated the BLM-induced up-regulation of mRNA expressions of collagen-1a1, collagen-3a1, and fibronectin (Fig. 2f–h). Furthermore, silencing Hoxaas3 eliminated BLM-treated increase of FRP, including fibronectin and a-SMA by western blot (Fig. 2i). These data suggested that Hoxaas3 inhibition attenuated BLM-induced PF in mice and that Hoxaas3 silencing is a potential treatment for PF.

Hoxaas3 is a transcriptional target of the TGF-β1/Smad4 pathway

In order to further clarify the signaling pathway of Hoxaas3 regulating PF, we investigated the upstream mechanism of Hoxaas3. Many researches have indicated that the TGF-β1/Smad4 signaling pathway played an important role in PF. Hoxaas3 level was found to be upregulated in cultured mouse lung fibroblasts (CMLF) treated with TGF-β1 (10 ng/ml) for 48 h in a dose-dependent manner (Fig. 3a). The PROMO online database (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) and JASPAR online database (http://jaspardb.genereg.net/) were used to predict Smad4 binding sequence (AGGAAAAACAT) at the promoter of Hoxaas3 with high scores. Smad4 was effectively inhibited by siRNA at both the mRNA (Fig. 3b) and the protein level (Fig. 3c). Smad4 inhibition reduced Hoxaas3 level in both control and TGF-β1-induced CMLF (Fig. 3d), indicating Smad4 may play a specific role in the stimulation of Hoxaas3 mediated by TGF-β1. ChIP assay was used to investigate whether Smad4 could bind to the promoter sequence of Hoxaas3. The level of Smad4 binding to the promoter of Hoxaas3 increased compared with the control group. IgG was as a negative control (Fig. 3e). These results showed Hoxaas3 is regulated by the TGF-β1/Smad4 pathway as its transcriptional target.
Hoxaas3 negatively regulates the function of miR-450b-5p to promotes fibrogenesis

We next investigated the downstream of Hoxaas3 regulating PF. Bioinformatics analysis, using the databases DIANA TOOLS, was performed to search for the target miRNA that has potential binding sites for Hoxaas3. We hypothesized that Hoxaas3 contributes to PF through modulation of miR-450b-5p. To address this question, Hoxaas3 sequences were transfected into fibroblasts (Fig. 4a). Overexpression of Hoxaas3 upregulated the mRNA expression of collagen-1a1 (Fig. 4b), collagen-3a1 (Fig. 4c), and fibronectin (Fig. 4d), whereas those changes were neutralized by upregulation of miR-450b-5p. In addition, upregulation of miR-450b-5p repressed Hoxaas3-induced increase of fibronectin, vimentin, and α-SMA by western blot (Fig. 4e). Proliferation and differentiation of fibroblasts play important role in PF, promoting ECM deposition and aggravating fibrosis. Overexpression of Hoxaas3 increased cell proliferation (Fig. 4f) and migration (Fig. 4g), whereas these results were neutralized by upregulation of miR-450b-5p. All of these data indicate that Hoxaas3 promotes fibrogenesis in CMLF by repressing miR-450b-5p.

To further investigate the relationship between Hoxaas3 and miR-450b-5p, a loss-of-function method was performed. Transfection of sh-Hoxaas3 diminished TGF-β1-induced the mRNA level of collagen-1a1 (Fig. S3A), collagen-3a1 (Fig. S3B), and fibronectin (Fig. S3C), whereas that function was nearly alleviated by the miR-450b-5p inhibitor, along with changes of fibronectin, vimentin, and α-SMA by western blot (Fig. S3D). Furthermore, inhibition of Hoxaas3 decreased the TGF-β1-induced proliferation (Fig. S3E) and migration (Fig. S3F), whereas these changes were also nearly alleviated with miR-450b-5p inhibitor. These results indicated that silencing Hoxaas3 inhibited TGF-β1-induced fibrogenesis through activation of miR-450b-5p.

Hoxaas3 regulates miR-450b-5p activity by acting as a competing endogenous RNAs (ceRNA)

Accumulating evidence has suggested that IncRNAs can play a role of ceRNA to bind to miRNA to regulate its activity. The expression of miR-450b-5p was found to be reduced in both the lung tissues of BLM-treated mice (Fig. 5a) and TGF-β1-treated CMLF (Fig. 5b). Forced of Hoxaas3 level decreased the miR-450b-5p level (Fig. 5c), whereas Hoxaas3 silencing increased miR-450b-5p (Fig. 5d) in CMLF. In addition, Hoxaas3 knockdown rescued the down-regulation of Hoxaas3 in BLM-treated mice (Fig. 5e).
A miR-450b-5p sensor luciferase vector, consisting of a perfect miR-450b-5p target sequence, which was integrated into the 3′ UTR of the luciferase gene, was designed to obtain better direct evidence of the interaction of Hoxaa3 with miR-450b-5p. Increased luciferase activity of miR-450b-5p sensor in CMLF transfected with Hoxaa3; Conversely, silencing of Hoxaa3 reduced luciferase activity of miR-450b-5p sensor.

Fig. 2 The knockdown of Hoxaa3 alleviates BLM-induced PF in mice. a The efficiency of sh-Hoxaa3 in fibroblasts was assessed via qPCR. b Intratracheal instillation of sh-Hoxaa3 decreased Hoxaa3 level compared with that in the BLM group based on qPCR. c Histological images and collagen deposition of the lung tissue was detected by H&E and Masson staining. d, e Fibrotic area (d) and HYP content (e) were detected in BLM-treated mice after infection with sh-Hoxaa3. f–h qPCR analysis of mRNA levels of collagen 1a1 (f), collagen 3a1 (g), and Fibronectin (h) in BLM-treated mice after knockdown of Hoxaa3. i Detection of Fibronectin and a-SMA level by western blot in BLM-treated mice after Hoxaa3 inhibition. (All data are presented as mean ± SD, n = 6, *p < 0.05).
In addition, Hoxaas3 overexpression reduces miR-450b-5p’s inhibitory effect on its sensors (Fig. 5g). Further evidence came from our research using a luciferase vector to have a Hoxaas3 fragment containing wild type (Hoxaas3-WT) or mutation (Hoxaas3-Mut) binding site for miR-450b-5p (Fig. 5h). miR-450b-5p inhibited the luciferase activity with Hoxaas3-WT in HEK293T cells, but miR-450b-5p missed its inhibitory function with Hoxaas3-Mut (Fig. 5i). These data suggested that Hoxaas3 regulates the expression and activity of miR-450b-5p by acting as a ceRNA.

miR-450b-5p regulates fibrogenesis by directly targeting the expression of Runx1

Next, miR-450b-5p mimic was transfected into CMLF to investigate whether miR-450b-5p has an anti-fibrotic effect during PF. Overexpression of miR-450b-5p neutralized TGF-β1-induced increase of the collagen-1a1 (Fig. 5A), collagen-3a1 (Fig. 5B), and fibronectin (Fig. 5C) by qPCR, along with the expression of fibronectin, vimentin and α-SMA by western blot (Fig. 5D). Furthermore, forced expression of miR-450b-5p abolished the TGF-β1-treated cell proliferation (Fig. 5E) and migration (Fig. 5F) of CMLF.

In order to further explore the anti-fibrotic mechanism of miR-450b-5p, Targetscan, miRanda and miRWalk databases were performed to find potential targets for miR-450b-5p. In that way, Runx1 3’ UTR was found to have perfect matching sites for miR-450b-5p. A luciferase reporter vector was established, containing wild type (Runx1-WT) or mutation (Runx1-Mut) binding site of miR-450b-5p (Fig. 6A). Luciferase assay showed that miR-450b-5p reduced Runx1-WT luciferase vector activity, but there was no relationship between miR-450b-5p and Runx1-Mut vector (Fig. 6B). Furthermore, miR-450b-5p inhibition increased the Runx1 expression (Fig. 6C, D), whereas upregulation of miR-450b-5p repressed the Runx1 level both at mRNA and protein levels (Fig. 6E, F). The results showed that miR-450b-5p directly suppressed Runx1 in a transcriptional manner.

In the rescue experiment, Hoxaas3 (WT) overexpression induced upregulation of Runx1 was recovered by co-transfection with miR-450b-5p mimics at both protein and mRNA levels (Fig. 6G, H). On the other hand, sh-Hoxaas3 induced downregulation of Runx1 was recovered by co-transfection with miR-450b-5p inhibitor at both protein and mRNA levels (Fig. 6I, J). Thus, Hoxaas3 regulates Runx1 by directly adsorbing miR-450b-5p.

Subsequently, we investigated the role of the Runx1 on miR-450b-5p inhibition promoting fibrogenesis. Runx1 was effectively inhibited by siRNA at both mRNA (Fig. 7A) and protein level (Fig. 7B). miR-450b-5p inhibition increase the mRNA level of collagen-1a1 (Fig. 7C), collagen-3a1 (Fig. 7D), and fibronectin (Fig. 7E), which was
Fig. 4 Hoxaas3 promotes fibrogenesis in cultured lung fibroblasts by inhibiting the function of miR-450b-5p. 

a. The expression of Hoxaas3 was detected via qPCR after Hoxaas3 transfection. 
b–d. qPCR analysis of mRNA levels of collagen 1a1 (b), collagen 3a1 (c), and Fibronectin (d) after transfection of Hoxaas3 together with miR-450b-5p. 

e. Western blot analysis of expression of Fibronectin, Vimentin, and a-SMA. 
f. Proliferative capacity was analyzed using an EDU assay. 
g. Wound-healing assays were performed to examine cell migration. (All data are presented as mean ± SD, n = 3, *P < 0.05).
nearly ameliorated by Runx1 knockdown, along with the expression of fibronectin, vimentin, and a-SMA by western blot (Fig. 7f). Furthermore, miR-450b-5p inhibitor increased proliferation (Fig. 7g) and migration (Fig. 7h), whereas Runx1 inhibition effectively alleviated these effects.

Hoxaas3 contributes to PF by regulating Runx1
Hoxaas3 inhibition reversed the upregulated mRNA expression of Runx1 in BLM-treated mice (Fig. 8b). Then, we found Runx1 inhibition attenuated the increase of the mRNA level for collagen-1a1 (Fig. 8c), collagen-3a1 (Fig. 8d), and fibronectin (Fig. 8e) in Hoxaas3-induced fibrogenesis, along with the expression of fibronectin, vimentin, and a-SMA by western blot (Fig. 8f). Meanwhile, it is similar to the effect of miR-450b-5p upregulation.

Discussion
Several lncRNAs have been discovered in PF through transcriptome sequencing and microarray analysis, etc.
Fig. 6 Runx1 is a direct target of miR-450b-5p. a Complementary sequences of miR-450b-5p and Runx1 are shown for the mouse, rat, and human genes. b Measurement of luciferase reporter assay demonstrates the interaction between miR-450b-5p and Runx1-WT or Runx1-Mut (fragment with the Runx1 3′-UTR containing the wild-type or mutant miR-450b-5p binding sites). c, e qPCR assays were performed to detect Runx1 mRNA expression after transfection of miR-450b-5p mimics or a miR-450b-5p inhibitor. d, f Western blot analysis of Runx1 protein levels in lung fibroblasts after transfection of miR-450b-5p mimics or a miR-450b-5p inhibitor. (All data are presented as mean ± SD, n = 3, *P < 0.05; NS, no significance). g, h The protein and mRNA levels of Runx1 in lung fibroblasts after transfection of pcDNA3.1-Hoxaas3 (WT), pcDNA3.1-Hoxaas3 (Mut), miR-450b-5p mimics, or co-transfection with pcDNA3.1-Hoxaas3 (WT) and miR-450b-5p mimics. i, j The protein and mRNA levels of Runx1 in lung fibroblasts after transfection of sh-Hoxaas3, miR-450b-5p inhibitor, or co-transfection with sh-Hoxaas3 and miR-450b-5p mimics.
Fig. 7 miR-450b-5p inhibition leads to fibrogenesis by regulating Runx1. a, b qPCR and western blot analysis of Runx1 mRNA (a) and protein (b) level in lung fibroblasts after transfection of miR-450b-5p inhibitor together with Runx1 inhibition. c–e qPCR analysis of mRNA levels of collagen 1a1 (c), collagen 3a1 (d), and Fibronectin (e). f Western blot analysis of expression of Fibronectin, Vimentin, and a-SMA. g Proliferative capacity was analyzed using an EdU assay. h Wound-healing assays were performed to examine cell migration. (All data are presented as mean ± SD, n = 3, *P < 0.05).
The mechanisms based on lncRNAs are one of the hot topics for PF at present. For example, lncPFAL was discovered to promote PF by competitively binding miR-18a to regulate CTGF. Song et al. investigated a novel lncITPF, which was upregulated in a TGF-β1-smad2/3-dependent manner, promotes PF through regulating...
hnRNP-L and ITGB1, and interestingly, IncITPF was also correlation with the clinicopathological characteristics of IPF patients. Zhao et al. found IncPFA contributed to PF through regulating the YAP1-Twist axis and playing the role of molecular sponge for miR-138. Jiang et al. showed IncPFRL contributed to the progression of PF by regulating miR-26a and Smad2. Liu et al. discovered a novel Inc-PCF, promoted PF by targeting miR-344a-5p and map3k11.

Hoxaas3 belongs to Hox gene cluster, regulating embryonic development, hematopoietic lineage, and differentiation, which is a group of highly homologous transcription factors. Zhang et al. detected Hoxaa3 increased in the pulmonary blood vessels and the pulmonary artery smooth muscle cells of mice under hypoxic status; meanwhile, Hoxaa3 level raised via histone H3 Lysine 9 acetylation, regulating cell cycle distribution. In this study, we firstly found Hoxaa3 was up-regulated in PF, and promoted fibrogenesis, indicating that Hoxaa3 might be a useful biomarker and a candidate drug target for PF.

TGF-β1 is involved in a variety of cellular processes, including proliferation, apoptosis, death, differentiation, angiogenesis, and motility. TGF-β1 activated its downstream molecules, phosphorylation of Smad2/3, to exert biological functions. In addition, phosphorylation of Smad2/3 binding with Smad4 to form a Smads complex, then get into the nucleus to combine target genes and control its expression. It is known that TGF-β1 plays an important role in PF regulation. However, the specific function of Smad4 in PF remains largely unclear. Considering the important role of Smad4 in TGF-β1/Smads signaling pathway, in this study, Smad4 was found to bind to the promoter sequence of Hoxaa3 to enhance its expression.

Cumulating evidence demonstrates that miRNAs play prominent roles in IPF. Several dysregulated miRNAs have been found in the human lungs as well as in animal models with PF. These abnormal miRNAs activated and differentiated fibroblasts to myofibroblasts, leading to proliferation and migration of fibroblasts, and excessive ECM accumulation. For example, miR-154 and miR-21 have been reported to be upregulated in PF and led to PF. In contrast, miR-101, miR-9-5p, and miR-18a-5p were downregulated and played an anti-fibrotic role in PF. In the previous report, miR-450b-5p level was reduced with TGF-β1, a new mechanism to inhibit myogenic differentiation of rhabdomyosarcoma. LncRNA and miRNA often regulate each other in a ceRNA model. In the present study, miR-450b-5p is downregulated in TGF-β1 treatment of lung fibroblasts and pulmonary tissues of BLM-treated mice. The expression and activity of miR-450b-5p were regulated by Hoxaa3, acting as a ceRNA in PF. Knockdown of miR-450b-5p promoted lung fibroblast, whereas upregulation of miR-450b-5p reduced TGF-β1-induced fibrogenesis in CMLF. miR-450b-5p played an anti-fibrotic role in PF.

Runt-related transcription factor 1 (Runx1), one of RUNX family members, including Runx1, Runx2, and Runx3, a family of evolutionarily conserved transcription factors, play a key function in a variety of diseases, such as tumors, pulmonary arterial hypertension, cardiac remodeling, etc. Runx1 has been shown to regulate EMT via promoting the Wnt/β-catenin signaling pathway in colorectal cancer. In addition, Runx1 played important role in liver fibrosis of non-alcoholic steatohepatitis patients. Interestingly, Runx1 was found to regulate EMT marker genes in renal tubular epithelial cells, and deletion of Runx1 could attenuate renal fibrosis. This study indicated miR-450b-5p reduced the Runx1 level at the transcriptional levels. In addition, Runx1 inhibition eliminates the profibrotic function of miR-450b-5p silencing. These results indicated that Runx1 was one of the targets of miR-450b-5p and mediated its anti-fibrotic effect.

In conclusion, our study showed the role and mechanism of the TGF-β1/Smad4-Hoxaa3–miR-450b-5p–Runx1 axis for a better understanding of PF (Fig. 8g), and demonstrated Hoxaa3 maybe a new diagnostic biomarker or potential therapeutic target for IPF.

Materials and methods

Primary tissue samples

Lung tissues from 18 IPF patients and 18 normal lung histology samples were obtained from Tissue Specimen Bank of the First Affiliated Hospital, College of Medicine, Zhejiang University. All participants provided written informed consent. The Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, approved this patient study.

Animal model and cell culture

The animal studies were approved by the Institutional Animal Care and Use Committee of Zhejiang University, Hangzhou, China. Male 6–8-week-old C57BL/6 mice were used in this study. Anesthetized mice received 5 mg/kg bleomycin (BLM, Nippon Kayaku, Tokyo, Japan) or an equal volume of sterile saline via intratracheal administration. The number of mice in each group was six.

In a separate set of experiments, mice were treated with either Lentivirus particles expressing nonsense short hairpin RNA (sh-Scramble) or shRNA targeting Hoxaa3 (sh-Hoxaa3) through intratracheal injection at a dose of 1×1011 vector genomes/mice, 3 day after BLM administration. On days 7, 14, 21, and 28, mice were sacrificed; lung tissue specimen were gathered and then frozen in liquid nitrogen for further studies.

Cultured mouse lung fibroblasts (CMLF) were isolated from 2-day-old C57BL/6 mice, as described previously. Lung tissues were cut into small pieces, digested with 0.25% trypsin following constituted shaking for about
90 min, and then passed through a 200-mesh cell strainer sieve. The cell was centrifuged and resuspended in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. CMLF was seeded into culture plates. Further experiments were performed when the cells were in good condition.

**Hematoxylin and Eosin (H&E) Staining and Masson’s Trichrome Staining**

Lung tissues were fixed in 4% paraformaldehyde for 24 h, and then embedding in paraffin, 4-mm sections were prepared and stained with H&E and Masson’s trichrome for histopathologic examination. The fibrotic area was quantified with Image Pro Plus 6.0.

**Measurement of Hydroxyproline content**

Matrix proteins in lung tissue were determined by Hydroxyproline (HYP) detection kit (Nanjing Jiancheng Institute of Bioengineering, China), following the manufacturer’s instructions. Briefly, the lung tissues were prepared, and then the mixture of oxidizing reagents was added and cultured at room temperature for 20 min. Next, the developer was added and incubated at 37°C for 5 min. Finally, the absorbance was measured at 560 nm. Data are expressed as micrograms of HYP per milligram dry weight of lung tissue.

**Western blot and quantitative real-time reverse-transcription PCR**

Western blot and quantitative real-time reverse-transcription PCR (qPCR) were performed as described previously. Lysates were generated, and total protein was separated by standard SDS PAGE, followed by transfer to polyvinylidene fluoride (PVDF) membranes. The membranes were then washed and blocked before incubation with the primary antibodies (listed in Table S1). Reactions were detected using enhanced chemiluminescence assays. GADPH was used as a control.

All procedures were performed according to the manufacturer’s instructions. Total RNA was extracted using an Ultrapure RNA kit (CWbio, Co., Ltd., Beijing, China). RNA was reverse-transcribed into cDNA using iScript cDNA Synthesis kits (Bio-Rad Laboratories, Hercules, CA, USA). Quantitative real-time PCR (qPCR) was performed using the SYBR-Green PCR kit (Thermo Fisher Scientific, Waltham, MA, USA) according to a standard protocol.

**Ethynyl deoxyuridine assay**

Ethynyl Deoxyuridine (EDU) was performed as described previously. Click-iT EDU Imaging Kit (Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer’s protocol. Briefly, cells were incubated with the IC50 of cisplatin for 48 h and then with 10 μM EDU for 2 h before fixation, permeabilization, and staining for Edu. Nuclei were counterstained with DAPI for 5 min. Wound healing assay was performed as described previously.

**Chromatin immunoprecipitation assays**

Chromatin immunoprecipitation (ChIP) assays were performed using a ChIP Assay Kit according to the manufacturer’s instructions (Cell Signaling Technology, SimpleChIP Plus Enzymatic Chromatin IP Kit (Magnetic Beads) #9005). The genomic DNA fragments were immunoprecipitated with antibodies against Smad4 and normal rabbit IgG (listed in Table S1) at 4°C for 3 h. After cross-linking reversal and DNA cleanup, the purified and precipitated DNA was analyzed by qPCR. The primers targeting the Hoxaas3 promoter region were 5′-CAATTGATCCCG GATTCCACA-3′ and 5′-CACCCCTTTCTGAAGGCTAAG TG-3′.

**Plasmid construction and transfection**

For Hoxaas3 overexpression, the full-length Hoxaas3 cDNA was cloned into vector pcDNA3.1, and stable clones were obtained with G418. Empty vector pcDNA3.1 was used as a negative control. For Hoxaas3 knockdown, shRNAs targeting Hoxaas3 (sh-Hoxaas3) and a scrambled shRNA (sh-Scram) used as negative control were synthesized. The miR-450b-5p mimics/miR-Ctrl, miR-450b-5p inhibitors/NC, si-Smad4/si-Control, si-Runx1/si-Control and respective negative controls were purchased from GenePharma (Shanghai, China). Transfection using Lipofectamine 3000 (L3000015, Thermo Fisher Scientific, Waltham, MA, USA) was performed according to a standard protocol.

**Luciferase reporter assay**

For the luciferase reporter assay, oligonucleotides containing the target sequence of Hoxaas3/Runx1 and its mutant form devoid of the miR-450b-5p-binding site were amplified and cloned into a pGL3 vector immediately downstream of the luciferase gene. To identify the influence of Hoxaas3/Runx1 on miR-450b-5p activity, an miR-450b-5p sensor reporter was constructed. Lung fibroblasts or HEK293 cells were transfected with the luciferase constructs and miRNAs using Lipofectamine 3000. Luciferase activity was measured at 36 h post transfection with a Dual-Luciferase assay system (Promega, Madison, WI, USA) according to the manufacturer’s protocols.

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). Unpaired Student’s t test was used for experiments comparing two groups, whereas one-way
ANOVA with Student-Newman-Keuls post hoc test was applied for experiments comparing three or more groups. The mean Standard Deviation (SD) of at least three independent experiments was determined. P-values < 0.05 were considered statistically significant.

Acknowledgements

This work was supported by the Zhejiang Provincial Key Discipline of Traditional Chinese Medicine (grant no. 2017-XK-A33 to J.H.), National Key R&D Program of China (grant no. 2017YFC0113500 to J.H., Grant No. 2018YFC001905 to X.A.), Key Research and Development Program of Zhejiang Provincial (grant no. 2020DC0538 to J.H.), Zhejiang Provincial Natural Science Foundation of China (grant no. LY19H160057 to S.L.), the Zhejiang Provincial Public Welfare Technology Research Plan of China (grant no. LGQ19040003 to X.A.), the Chinese Medicine Science and Technology Plan of Zhejiang Province (grant no. 2019ZA070 to X.A.).

Author details

1. Department of Thoracic Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
2. Department of Internal Medicine, Hangzhou West Lake Sanatorium, the Affiliated Hangzhou First People’s Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
3. Department of Thoracic Surgery, Henan Province People’s Hospital, Zhengzhou, Henan, China.
4. Department of Surgery, Zhejiang University Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
5. Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
6. Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
7. Department of Anesthesiology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The Institutional Research Board of the First Affiliated Hospital, College of Medicine, Zhejiang University, approved this study.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at https://doi.org/10.1038/s41419-020-02889-w.

Received: 8 December 2019 Revised: 31 July 2020 Accepted: 31 July 2020 Published online: 26 August 2020

References

1. Lederer, D. J. & Martinez, F. J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 378, 1811–1823 (2018).
2. Richeldi, L., Collard, H. R. & Jones, M. G. Idiopathic pulmonary fibrosis. Lancet 389, 1941–1952 (2017).
3. Hutchinson, J., Fogarty, A., Hubbard, R. & McKeever, T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 46, 795–806 (2015).
4. Wotman, P. J., Collard, H. R. & Jones, K. D. Pathogenesis of idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 190, 897–906 (1964).
5. Zhang, X. et al. Catedravaric attenuates experimental pulmonary fibrosis in vivo and in vivo. Front. Pharmacol. 10, 903 (2019).
6. Baghu, G. J. Idiopathic pulmonary fibrosis: combating on a new turf. Lancet Respir. Med. 4, 430–432 (2016).
7. Liu, Y. M., Nepali, K. & Liu, J. P. Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets. J. Med. Chem. 60, 527–535 (2017).
8. Ma, X. et al. Analyze and identify pemoline target EGFR improve lung function and alleviate pulmonary fibrosis to prevent exacerbation of chronic obstructive pulmonary disease by phosphochoerinexynes analysis. Front. Pharmacol. 10, 737 (2019).
9. Vancher, C. et al. Nintedanib with add-on pifendone in idiopathic pulmonary fibrosis: Results of the INJOURNEY Trial. Am. J. Respir. Crit. Care Med. 197, 356–363 (2018).
10. Kopp, F. & Mendell, J. T. Functional classification and experimental dissection of long noncoding RNAs. Cell 172, 393–407 (2018).
11. Bermudez, M. et al. LncRNAs as regulators of autophagy and drug resistance in colorectal cancer. Front. Oncol. 9, 1008 (2019).
12. Quinn, J. J. & Chang, H. Y. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17, 47–62 (2016).
13. Lin, S. et al. Metanalysis of atragalis-containing traditional chinese medicine combined with chemotherapy for colorectal cancer efficacy and safety to tumor response. Front. Oncol. 9, 749 (2019).
14. Sun, T. et al. Expression of IncRNA MIR222HG co-transcribed from the miR-222/221 gene promoter facilitates the development of castration-resistant prostate cancer. Oncogenesis 7, 30 (2018).
15. Lin, S. et al. LncRNA HOXA-A5 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells. Oncogenesis 8, 6 (2019).
16. Sun, H. et al. Integrated long non-coding RNA analyses identify novel regulator networks of epithelial-mesenchymal transition in the mouse model of pulmonary fibrosis. J. Cell Mol. Med. 20, 1234–1246 (2016).
17. Li, X. et al. IncRNA PFAL promotes lung fibrosis through CTGF by competitively binding miR-18a. FASEB J. 32, S258–S259 (2018).
18. Song, X. et al. InTTPF promotes pulmonary fibrosis by targeting hnrNP-L depending on its host gene TGFBI. Mol. Ther. 27, 380–393 (2019).
19. Zhao, X. et al. IncRNA PFAR promotes lung fibroblast activation and fibrosis by targeting miR-138 to regulate the YAP1-twist axis. Mol. Ther. 26, 2206–2217 (2018).
20. Jiang, H. et al. Inhibition of IncRNA PFFL prevents pulmonary fibrosis by disrupting the miR-25a/miR222 loop. Am. J. Physiol. Lung Cell. Mol. Physiol. 315, L563–L575 (2018).
21. Liu, H. et al. A novel Inc-PCF promotes the proliferation of TGF-beta1-activated epithelial cells by targeting miR-344a-5p to regulate map3k11 in pulmonary fibrosis. Cell Death Dis. 8, e3137 (2017).
22. Saurin, A. J., Delphi, M. C., Maurer-Zaffran, C. & Graba, Y. The generic facet of Hopx protein function. Trends Genet. 34, 941–953 (2018).
23. Deschamps, J. & Duboule, D. Embryonic timing, axial stem cells, chromatin dynamics, and the Hox clock. Genes Dev. 31, 1406–1416 (2017).
24. Zhang, H. et al. Long non-coding RNA Hoxa3 contributes to hypoxia-induced pulmonary artery smooth muscle cell proliferation. Cardiovasc. Res. 115, 647–657 (2019).
25. Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-beta: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325–338 (2016).
26. Bisey, P. A. et al. Dysregulation of the MRH499 target TGFBI alters the TGFbeta pathway to induce cisplatin resistance in nasopharyngeal carcinoma. Oncogenesis 7, 40 (2018).
27. Moren, A. et al. LXRalpha limits TGFbeta-dependent hepatocellular carcinoma associated fibroblast differentiation. Oncogenesis 8, 36 (2019).
28. Stewart, A. G., Thomas, B. & Koff, J. TGF-beta: master regulator of inflammation and fibrosis. Respir. Pathology 23, 1096–1097 (2018).
29. Zhao, H. et al. Transforming growth factor beta1/Med4 signaling affects osteoblast differentiation via regulation of miR-155 expression. Mol. Cells 40, 221–227 (2017).
30. Akhurst, R. J. & Hata, A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790–811 (2012).
31. Huang, C. et al. MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. J. Biol. Chem. 292, 16420–16437 (2017).
32. Mikovic, J. et al. Profibrotic role of miR-154 in pulmonary fibrosis. Am. J. Respiratory cell Mol. Biol. 47, 879–887 (2012).
33. Kang, H. Role of microRNAs in TGF-beta signaling pathway-mediated pulmonary fibrosis. Int. J. Mol. Sci. 18, 2527 (2017).
34. Liu, G. et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207, 1589–1597 (2010).
35. Ferro-Fernandez, M. et al. miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2. EMBO Rep. 16, 1358–1358 (2015).
36. Zhang, Q. et al. miR-18a-5p inhibits sub-pleural pulmonary fibrosis by targeting TGF-beta receptor II. *Mol. Ther.* **25**, 728–738 (2017).
37. Sun, M. M. et al. TGF-beta1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. *Oncogene* **33**, 2075–2086 (2014).
38. Sood, R., Kamikubo, Y. & Liu, P. Role of RUNX1 in hematological malignancies. *Blood* **129**, 2070–2082 (2017).
39. Liang, O. D. et al. Endothelial to haematopoietic transition contributes to pulmonary arterial hypertension. *Cardiovasc. Res.* **113**, 1560–1573 (2017).
40. McCarroll, C. S. et al. Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. *Circulation* **137**, 57–70 (2018).
41. Li, Q. et al. RUNX1 promotes tumor metastasis by activating the Wnt/beta-catenin signalling pathway and EMT in colorectal cancer. *J. Exp. Clin. Cancer Res.* **38**, 334 (2019).
42. Kaur, S. et al. Increased expression of RUNX1 in liver correlates with NASH activity score in patients with non-alcoholic steatohepatitis (NASH). *Cells* https://doi.org/10.3390/cells8101277 (2019).
43. Zhou, T. et al. Runt-related transcription Factor 1 (RUNX1) promotes TGF-beta-induced renal tubular epithelial-to-mesenchymal transition (EMT) and renal fibrosis through the PI3K Subunit p110delta. *EBioMedicine* **31**, 217–225 (2018).
44. Lin, S. et al. NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma. *Oncol. Rep.* **36**, 853–862 (2016).